We were delighted to talk with Dr Kristin Kaasen Jørgensen (Akershus University Hospital, Nordbyhagen, Norway) around the NOR-DRUM B study, investigating proactive therapeutic drug monitoring during maintenance therapy with infliximab.
The abstract entitled ‘Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study’(Presentation no. OP09) was presented at the 17th Congress of ECCO, February 16-19, 2022!
Questions
- What are the current limitations of biologic drugs in IBD? (0:19)
- What are the potential benefits and pitfalls of a proactive therapeutic drug monitoring as opposed to a reactive strategy? (1:08)
- What were the aims and design of the NOR-DRUM B study? (2:49)
- What were the study endpoints and how well were these achieved? (4:24)
- What will be the impact of these findings on clinical practice? (5:36)
Disclosures: Kristin Kaasen Jørgensen has received personal fees from Roche, BMS, and Norgine.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual 2022.
